Early use of recombinant human erythropoietin promotes neurobehavioral development in preterm infants.
- Author:
Jin-Shui HE
1
;
Zhong-Ling HUANG
;
Hong YANG
;
Kai-Zhi WENG
;
Shao-Bo ZHU
Author Information
- Publication Type:Journal Article
- MeSH: Anemia; prevention & control; Brain; drug effects; physiology; Child Development; drug effects; Erythropoietin; therapeutic use; Female; Humans; Infant Behavior; drug effects; Infant, Newborn; Infant, Premature; growth & development; Infant, Premature, Diseases; prevention & control; Male; Recombinant Proteins
- From: Chinese Journal of Contemporary Pediatrics 2008;10(5):586-588
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the effect of the early use of recombinant human erythropoietin (rhu-EPO) on neurobehavioral development in preterm infants.
METHODSForty-four preterm infants (30 males and 14 females) were randomly divided into two groups: Rhu-EPO treatment and untreated control (n=22 each). From postnatal day 7, the Rhu-EPO treatment group received intravenous rhu-EPO (250 IU/kg3 times weekly) for 4 weeks. A Neonatal Behavioral Neurological Assessment (NBNA) was performed at 40 weeks of corrected gestational age. A Gesell Development Schedule was used to evaluate neurological development 6 and 12 months after birth.
RESULTSThe NBNA score in the rhu-EPO treatment group (36.20+/-0.75) was significantly higher than that in the control group (34.40+/-1.05) at 40 weeks of corrected gestational age (P<0.05). The developmental quotient of fine motor in the rhu-EPO treatment group was significantly higher than that in the control group 6 months after birth (P<0.05). By 12 months after birth, the developmental quotient of gross motor, fine motor and language in the rhu-EPO treatment group was significantly higher than that in the control group (P<0.05).
CONCLUSIONSEarly use of Rhu-EPO can promote neurobehavioral development in preterm infants.
